Document is current
Any future updates will be listed below
-
Authors
Rainey-Smith, Stephanie R.
Mazzucchelli, Gavin N. http://orcid.org/0000-0001-5819-3026
Villemagne, Victor L.
Brown, Belinda M.
Porter, Tenielle
Weinborn, Michael
Bucks, Romola S.
Milicic, Lidija
Sohrabi, Hamid R. http://orcid.org/0000-0001-8017-8682
Taddei, Kevin
Ames, David
Maruff, Paul
Masters, Colin L.
Rowe, Christopher C.
Salvado, Olivier
Martins, Ralph N.
Laws, Simon M. http://orcid.org/0000-0002-4355-7082
,
- License Information
-
More Information
Article History
Received: 9 September 2017
Revised: 22 November 2017
Accepted: 30 December 2017
First Online: 26 February 2018
Conflict of interest
: C.L.M. is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. P.M. is a full-time employee of Cogstate Ltd. D.A. has served on scientific advisory boards for Novartis, Eli Lilly, Janssen, and Pfizer Inc. R.N.M. is a consultant to Alzhyme. C.C.R. has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca; has received speaker honoraria from Bayer Pharma and GE Healthcare; and has received research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. H.R.S. has received/is receiving remunerations from the Australian Alzheimer’s Research Foundation for working on several of their clinical trials associated with Takeda, Merck and AstraZeneca and Eli Lilly. VLV served as a consultant for Bayer Pharma; and received research support from a NEDO grant from Japan. S.M.L. has previously been a paid consultant to Alzhyme. The remaining authors declare that they have no conflict of interest.
